Time: 1:30pm - 2:20pm (ET), 10:30am - 11:20am (PT)
Date: Friday, November 19th 2021
Location: Virtual, hosted on the AMP Virtual Experience Platform
Abstract: Comprehensive genomic profiling of FFPE tissues through NGS empowers the advancement of clinical research. Roche has developed a Research Use Only test, the AVENIO Tumor Tissue CGP Kit, which is designed to match Foundation Medicine’s 324 gene FoundationOne®CDx Panel content. This new kit provides laboratories with distributed reagents and a cloud-based analysis software, for an end-to-end in-house solution to profile 324 genes associated with solid tumors across multiple cancer types, including genomic loss of heterozygosity, microsatellite instability, and tumor mutation burden. Here, we report high reproducibility and performance across five laboratory sites using a characterized panel of FFPET samples.